APA (7th ed.) Citation

Marston, N. A., Kamanu, F. K., Nordio, F., Gurmu, Y., Roselli, C., Sever, P. S., . . . Ruff, C. T. (2020). Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial. Circulation (New York, N.Y.), 141(8), 616-623. https://doi.org/10.1161/CIRCULATIONAHA.119.043805

Chicago Style (17th ed.) Citation

Marston, Nicholas A., et al. "Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial." Circulation (New York, N.Y.) 141, no. 8 (2020): 616-623. https://doi.org/10.1161/CIRCULATIONAHA.119.043805.

MLA (9th ed.) Citation

Marston, Nicholas A., et al. "Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial." Circulation (New York, N.Y.), vol. 141, no. 8, 2020, pp. 616-623, https://doi.org/10.1161/CIRCULATIONAHA.119.043805.